Risdiplam

[MAF] Risdiplam Powder For Oral Solution 0.75 mg/mL

1. Additional clinical criteria applies

2. Treatment of symptomatic Type 1, 2 or 3 spinal muscular atrophy (SMA) in patients who are/were 18 years of age or under at the time of initial treatment with risdiplam or nusinersen.

3. Treatment of symptomatic Type 1, 2 or 3 SMA in patients aged 19 years or above who had not initiated treatment with risdiplam or nusinersen prior to 19 years of age despite onset of signs/symptoms of SMA.

4. Treatment of pre-symptomatic SMA in patients who are/were under 3 years of age at the time of initial treatment with risdiplam or nusinersen.

5. Treatment of SMA in patients who have experienced a regression in a developmental state despite treatment with gene therapy.

Legend

This section shows the following:

• Subsidy Scheme and Clinical Indication (where applicable) of drugs listed in the MOH List of Subsidised Drugs

• Subsidised brands of vaccines recommended in the National Immunisation Schedules listed in the MOH Subsidised Vaccine List

• Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List

As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.

04/06/2024 Nusinersen and risdiplam for treating spinal muscular atrophy

The Ministry of Health’s Drug Advisory Committee has recommended:

• Risdiplam 0.75 mg/mL powder for oral solution for treating:

  • Symptomatic Type 1, 2 or 3 spinal muscular atrophy (SMA) in patients who are/were 18 years of age or under at the time of initial treatment with risdiplam or nusinersen;

  • Symptomatic Type 1, 2 or 3 SMA in patients aged 19 years or above who had not initiated treatment with risdiplam or nusinersen prior to 19 years of age despite onset of signs/symptoms of SMA;

  • Pre-symptomatic SMA in patients who are/were under 3 years of age at the time of initial treatment with risdiplam or nusinersen; and

  • SMA in patients who have experienced a regression in a developmental state despite treatment with gene therapy.

Funding status

[R] Risdiplam 0.75 mg/mL powder for oral solution is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications from 1 August 2024.

[R] Risdiplam should be used in line with the additional clinical criteria listed in the Annex.

[NR] MAF assistance does not apply to nusinersen for treating SMA.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration